Premium
Treatment of Candida infections with fluconazole in adult liver transplant recipients: Is TDM‐guided dosing adaptation helpful?
Author(s) -
Righi Elda,
Carnelutti Alessia,
Baccarani Umberto,
Sartor Assunta,
Cojutti Piergiorgio,
Bassetti Matteo,
Pea Federico
Publication year - 2019
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13113
Subject(s) - fluconazole , medicine , invasive candidiasis , dosing , therapeutic drug monitoring , gastroenterology , mycosis , retrospective cohort study , surgery , antifungal , pharmacokinetics , dermatology
Background Fluconazole represents a common antifungal option for the treatment of Candida infections in liver transplant recipients. Although adequate antifungal exposure is known to correlate with favorable outcomes in patients with invasive candidiasis, therapeutic drug monitoring (TDM) of fluconazole is currently not recommended. Methods We conducted a retrospective study including adult liver transplant recipients receiving fluconazole for invasive candidiasis and undergoing TDM. We assessed the correlation between clinical variables, fluconazole trough plasma levels (C min ), and outcome. Results Twenty‐seven patients (74% males; median age 57 years) were included. Abdominal candidiasis was the most frequent infection (56%). Median duration of fluconazole therapy was 17 days (IQR 9‐21). Fluconazole median C min was 11.0 mg/L (range 2.4‐30.6 mg/L). Five (19%) patients required TDM‐guided fluconazole dose increase. All‐cause in hospital mortality was 33%. Fluconazole C min >11 mg/L significantly correlated with clinical success (OR 8.78, 95% CI 1.13‐67.8, P = 0.04). Conclusions Our study identified decreased fluconazole C min as a factor associated with negative outcomes in liver transplant recipients with Candida infection. TDM of fluconazole may be advisable in this patient population.